Efficacy and safety of lenvatinib in 124 Japanese patients with anaplastic thyroid cancer

被引：2
|
作者：
Takahashi, Shunji [1 ]
Tahara, Makoto [2 ]
Ito, Koichi [3 ]
Tori, Masayuki [4 ]
Sakata, Yukinori [5 ]
Ishii, Mika [6 ]
Yoishida, Akira [6 ]
机构：
[1] Japanese Fdn Canc Res, Inst Canc, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Tokyo, Japan
[3] Ito Hosp, Tokyo, Japan
[4] Osaka Police Hosp, Osaka, Japan
[5] Eisai Col Ltd, Tokyo, Japan
[6] Kanagawa Hlth Serv Assoc, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz338.094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO3 - 3 -
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib
    Fukuda, Naoki
    Toda, Kazuhisa
    Fujiwara, Y. U.
    Wang, Xiaofei
    Ohmoto, Akihiro
    Urasaki, Tetsuya
    Hayashi, Naomi
    Sato, Yasuyoshi
    Nakano, Kenji
    Yunokawa, Mayu
    Ono, Makiko
    Tomomatsu, Junichi
    Mitani, Hiroki
    Takahashi, Shunji
    IN VIVO, 2020, 34 (05): : 2859 - 2864
  • [42] Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe
    Barbaro, Daniele
    Lapi, Paola
    Viacava, Paolo
    Torregrossa, Liborio
    BMJ CASE REPORTS, 2020, 13 (12)
  • [43] Relationship between Adverse Events and Efficacy of Lenvatinib for Thyroid Cancer
    Goto, Hideaki
    Kiyota, Naomi
    Chayahara, Naoko
    Takenaka, Kei
    Imamura, Yoshinori
    Nishimura, Meiko
    Toyoda, Masanori
    Mukohara, Toru
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Lenvatinib in thyroid cancer
    Ferrari, Silvia Martina
    Fallahi, Poupak
    Antonelli, Alessandro
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S31 - S31
  • [45] Efficacy of adavosertib therapy against anaplastic thyroid cancer
    Lu, Yu-Ling
    Huang, Yu-Tung
    Wu, Ming-Hsien
    Chou, Ting-Chao
    Wong, Richard J.
    Lin, Shu-Fu
    ENDOCRINE-RELATED CANCER, 2021, 28 (05) : 311 - 324
  • [46] The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies
    Cao, Ru-Bo
    Ge, Yao
    Zhang, Wen-Xuan
    Lin, Guo-He
    Kuang, Bo-Hua
    Wang, Bi-Cheng
    MEDICINE, 2024, 103 (31)
  • [47] Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
    Yamazaki, Haruhiko
    Iwasaki, Hiroyuki
    Suganuma, Nobuyasu
    Toda, Soji
    Masudo, Katsuhiko
    Nakayama, Hirotaka
    Rino, Yasushi
    Masuda, Munetaka
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2019,
  • [48] A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib
    Hamamoto, Takao
    Kono, Takashi
    Taruya, Takayuki
    Ishino, Takashi
    Ueda, Tsutomu
    Takeno, Sachio
    AURIS NASUS LARYNX, 2020, 49 (03) : 515 - 519
  • [49] Nasogastric administration of lenvatinib solution in a mechanically ventilated patient with rapidly growing anaplastic thyroid cancer
    Kawano, Fumiaki
    Yonekawa, Tadato
    Yamaguchi, Hideki
    Shibata, Nobuhiro
    Tashiro, Kousei
    Ikenoue, Makoto
    Munakata, Shun
    Higuchi, Kazuhiro
    Tanaka, Hiroyuki
    Sato, Yuichiro
    Hosokawa, Ayumu
    Takeno, Shinsuke
    Nakamura, Kunihide
    Nanashima, Atsushi
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2020, : 1 - 6
  • [50] Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report
    Luongo, Cristina
    Porcelli, Tommaso
    Sessa, Francesca
    De Stefano, Maria Angela
    Scavuzzo, Francesco
    Damiano, Vincenzo
    Klain, Michele
    Bellevicine, Claudio
    Matano, Elide
    Troncone, Giancarlo
    Schlumberger, Martin
    Salvatore, Domenico
    CURRENT ONCOLOGY, 2021, 28 (06) : 5401 - 5407
12345